References
- Araoka H., Yoneyama A.: Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis. 14, 355–363 (2012)
- Avison M.B., Higgins C.S., von Heldreich C.J., Walsh T.R.: Plasmid location and molecular heterogeneity of the L1 and L2 β-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 45, 413–419 (2001)
- Aydemir C., Aktas E., Eldes N., Kutsal E., Demirel F., Ege A.: Community-acquired infection due to Stenotrophomonas maltophilia: a rare cause of septic arthritis. Turk J Pediatr. 50, 89–90 (2008)
- Bartoszek D., Fleischer M.: Znaczenie kliniczne Stenotrophomonas maltophilia. Forum zakażeń, 4, 165–171 (2013)
- Belzer A., Weiss E., Etaee F., Bunick C.G., Damsky W., Nelson C.A.: Stenotrophomonas maltophilia, a Pathogen of Increasing Relevance to Dermatologists: A Case Report and Review of the Literature. Antibiotics, 11, DOII:10.3390/antibiotics11101398 (2022)
- Bin Abdulhak A.A., Zimmerman V., Al Beirouti B.T., Baddour L.M., Tleyjeh I.M.: Stenotrophomonas maltophilia infections of intact skin: a systematic review of the literature. Diagn Microbiol Infect Dis. 63, 330–333 (2009)
- Bostanghadiri N., Ghalavand Z., Fallah F., Yadegar A., Ardebili A., Tarashi S., Pournajaf A., Mardaneh J., Shams S., Hashemi A.: Characterization of Phenotypic and Genotypic Diversity of Stenotrophomonas maltophilia Strains Isolated From Selected Hospitals in Iran. Front Microbiol. 10, DOI:10.3389/fmicb.2019.01191 (2019)
- Brooke J.S.: Advances in the microbiology of Stenotrophomonas maltophilia. Clin Microbiol Rev. 34, DOI:10.1128/CMR.00030-19 (2021)
- Brooke J.S.: Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin. Microbiol Rev. 25, 2–41 (2012)
- Chang Y.T., Lin C.Y., Chen Y.H., Hsueh P.R.: Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol. 6, DOI:10.3389/fmicb.2015.00893 (2015)
- Chen S., Zou D.: Prognosis of hospital-acquired pneumonia/ventilator-associated pneumonia with Stenotrophomonas maltophiliaversus, Klebsiella pneumoniae in intensive care unit: A retrospectivecohort study. Clin Respir J. 16, 669–676 (2022)
- Clinical and Laboratory Standards Institute. M100: Performance Standards for Antimicrobial Susceptibility Testing. 31 ed. Wayne, PA, 2021,
https://clsi.org/media/z2uhcbmv/m100ed31_sample.pdf (14.03.2023) - Cowart MC, Ferguson CL.: Optimization of Aztreonam in Combination With Ceftazidime/Avibactam in a Cystic Fibrosis Patient With Chronic Stenotrophomonas maltophilia Pneumonia Using Therapeutic Drug Monitoring: A Case Study. Ther Drug Monit. 43, 146–149 (2021)
- Duan Z., Qin J., Liu Y., Li C., Ying C.: Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital. BMC Microbiol. 20, DOI:10.1186/s12866-020-01985-3 (2020)
- Dzierżanowska D.: Antybiotykoterapia praktyczna. α-medica press, Bielsko-Biała, 2018
- Farrell D.J., Sader H.S., Jones R.N.: Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother. 54, 2735–2737 (2010)
- Fluit, A.C., Bayjanov, J.R., Aguilar, M.D., Cantón R., Elborn S., Tunney M.M., Scharringa J., Benaissa-Trouw B.J., Ekkelenkamp M.B.: Taxonomic position, antibiotic resistance and virulence factor production by Stenotrophomonas isolates from patients with cystic fibrosis and other chronic respiratory infections. BMC Microbiol. 22, DOI:10.1186/s12866-022-02466-5 (2022)
- Forrester J.B., Steed L.L, Santevecchi B.A., Flume P., Palmer-Long G.E., Bosso J.A.: In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates. Open Forum Infect Dis. 5, DOI:10.1093/ofid/ofy158 (2018)
- Gajdács M., Urbán E.: A 10-year single-center experience on Stenotrophomonas maltophilia resistotyping in Szeged, Hungary. Eur J Microbiol Immunol (Bp). 10, 91–97 (2020)
- Gajdacs M., Urban E.: Prevalence and antibiotic resistance of Stenotrophomonas maltophilia in respiratory track: a 10-year epidemiological snapshot. Health Serv Res Manag Epidemiol. 15, DOI:0.1177/2333392819870774 (2019)
- Gallagher T., Phan J., Oliver A., Chase A.B., England W.E., Wandro S., Hendrickson C., Riedel S.F., Whiteson K.: Cystic fibrosis-associates Stenotrophomonas maltophilia strain specific adaptations and responses to pH. J Bacteriol. 13, DOI:10.1128/JB.00478-18 (2019)
- Geller M., Nunes C.P., Oliviera L., Nigri R.: S. maltophilia pneumonia: a case report. Respir Med Case Rep. 24, 44–45 (2018)
- Gibb J.; Wong D.W.: Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies. Antibiotics, 10, DOI:10.3390/antibiotics10101226 (2021)
- Gordon N.C., Wareham D.W.: Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother. 65, 483–489 (2010)
- Granchelli A.M., Adler F.R., Keogh R.H., Kartsonaki C., Cox D.R., Liou T.G.: Microbial Interactions in the cystic fibrosis airway. J Clin Microbiol. 56, DOI: 10.1128/JCM.00354-18 (2018)
- Grillon A., Schramm F., Kleinberg M., Jehl F.: Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies. PLoS One, 11, DOI:10.1371/journal.pone.0156690 (2016)
- Guerci P., Bougle A. i wsp. AZUREA research network.: Outcomes of Stenotrophomonas maltophilia hospital-aquired pneumonia in intensive care unit: a nationwide retrospective study. Crit Care. 23. DOI: 10.1186/s13054-019-2649-5 (2019)
- Healthcare-associated infections in intensive care units – Annual Epidemiological Report for 2017. European Centre for Disease Prevention and Control, 2019,
https://www.ecdc.europa.eu/en/publications-data/healthcare-associated-infections-intensive-care-units-annual-epidemiological-1 (14.03.2023) - Huan Y., Kong Q., Mou H., Yi H.: Antimicrobial Peptides: Classification, Design, Application and Research Progress in Multiple Fields. Front. Microbiol. 11, DOI:10.3389/fmicb.2020.582779 (2020)
- Huertas Méndez N.J., Vargas Casanova Y., Gómez Chimbi A.K., Hernández E., Leal Castro A.L., Melo Diaz J.M., Rivera Monroy Z.J., García Castañeda J.E.: Synthetic Peptides Derived from Bovine Lactoferricin Exhibit Antimicrobial Activity against E. coli ATCC 11775, S. maltophilia ATCC 13636 and S. enteritidis ATCC 13076. Molecules, 22, DOI:10.3390/molecules22030452 (2017)
- IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections: Version 2.0,3/31/2022
https://www.idsociety.org/news-publications-new/articles/2021/new-guidance-for-treating-antimicrobial-resistantinfections-released/ (14.03.2023) - Imoto W., Kakeya H. i wsp.: Clinical characteristics of rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia. Intern Med. 59, 193–198 (2020)
- Insuwanno W., Kiratisin P., Jitmuang A.: Stenotrophomonas maltophilia Infections: Clinical Characteristics and Factors Associated with Mortality of Hospitalized Patients. Infect. Drug. Resist. 13, 1559–1566 (2020)
- Jacobson S., Junco Noa L., Wallace M.R., Bowman M.C.: Clinical outcomes using minocycline for Stenotrophomonas maltophilia infections. J Antimicrob Chemother. 71, 3620–3622 (2016)
- Jiang Z., Ren Y., Zhang C., Yin Y., Li C.: Community-Acquired Stenotrophomonas Maltophilia Infection in a Child: A Case Report and Literature Review. Infect Drug Resist. 15, 5469–5474 (2022)
- Kalidasan V., Joseph N., Kumar S., Awang Hamat R., Neela V.K.: Iron and Virulence in Stenotrophomonas Maltophilia: All We Know So Far. Front. Cell. Infect. Microbiol. DOI:10.3389/fcimb.2018.00401 (2018)
- Kanchanasuwan S., Rongmuang J., Siripaitoon P.; Kositpantawong N., Charoenmak B., Hortiwakul T., Nwabor O.F., Chusri S.: Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Patients with Stenotrophomonas maltophilia Bacteremia. J. Clin. Med. 11, DOI:10.3390/jcm11113085 (2022)
- Khan A., Pettaway C., Dien B.J., Arias C.A., Bhatti M.M., Humphries R.M.: Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 65, DOI:10.1128/AAC.02631-20 (2021)
- Kim E.J., Kim Y.C., Ahn J.Y., Jeong S.J., Ku N.S., Choi J.Y., Yeom J., Song Y.G.: Risk factors for mortality in patients with Stenotrophomonas maltophilia bacteriemia and clinical impact of quinolone-resistant strains. BMC Infect Dis. 19, DOI:10.1186/s12879-019-4394-4 (2019)
- Mahdi O., Eklund B., Fisher N.: Laboratory culture and maintenance of Stenotrophomonas maltophilia. Curr. Protoc. Microbiol. DOI:10.1002/9780471729259.mc06f01s32 (2014)
- Martinez-Servat S., Yero D., Huedo P., Marquez R., Molina G., Daura X., Gibert I.: Heterogeneous Colistin-Resistance Phenotypes Coexisting in Stenotrophomonas maltophilia Isolates Influence Colistin Susceptibility Testing. Front. Microbiol. 9, DOI:10.3389/fmicb.2018.02871 (2018)
- Menetrey Q., Sorlin P., Jumas-Bilak E., Chiron R., Dupont C., Marchandin H. Achromobacter xylosoxidans and Stenotrophomonas maltophilia: emerging pathogens well-armed for life in the cystic fibrosis patients’ lung. Genes, 12, DOI:10.3390/genes12050610 (2021)
- Mojica M.F., Humphries R., Lipuma J.J., Mathers A.J., Rao G.G., Shelburne S.A., Fouts D.E., Van Duin D., Bonomo R.A.: Clinical challenges treating Stenotrophomonas maltophilia infections: an update. JAC Antimicrob. Resist. DOI:10.1093/jacamr/dlac040 (2022)
- Mojica M.F., Rutter J.D., Taracila M., Abriata L.A., Fouts D.E., Papp-Wallace K.M., Walsh T.J., LiPuma J.J., Vila A.J., Bonomo R.A.: Population Structure, Molecular Epidemiology, and beta-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States. mBio, 10, DOI:10.1128/mBio.00405-19 (2019)
- Moriceau C., Eveillard M., Lemarié C., Chenouard R., Pailhoriès H., Kempf M.: Stenotrophomonas maltophilia susceptibility to ceftazidime-avibactam combination versus ceftazidime alone. Méd. Mal. Infect. 50, 305–307 (2020)
- Morrissey I., Olesky M., Hawser S., Lob S.H., Karlowsky J.A., Corey G.R., Bassetti M., Fyfe C.: In Vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017. Antimicrob. Agents Chemother. 64, DOI:10.1128/AAC.01699-19 (2020)
- Okazaki A., Avison M.B.: Aph(3′)-IIc, an aminoglycoside resistance determinant from Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 51, 359–360 (2007)
- Osawa K., Shigemura K., Kitagawa K., Tokimatsu I., Fujisawa M.: Risk factors for death from Stenotrophomonas maltophilia bacteriemia. J Infect Chemother. 24, 632–636 (2018)
- Pompilio A., Di Bonaventura G. i wsp.: Potential novel therapeutic strategies in cystic fibrosis: Antimicrobial and anti-biofilm activity of natural and designed – helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa and Stenotrophomonas maltophilia. BMC Microbiol. 12, DOI:10.1186/1471-2180-12-145 (2012)
- Rello J., Kalwaje E.V., Lagunes L., Alves J., Wunderink R.G., Conway-Morris A., Rojas J.N., Alp E., Zhang Z.: A global priority list of the TOp TEn resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis. Eur J Clin Microbiol Infect Dis. 38, 319–323 (2019)
- Said M.S., Tirthani E., Lesho E.: Stenotrophomonas maltophilia. StatPearls, Treasure Island, Floryda, StatPearls, 2022
- Simner P.J., Patel R.: Cefiderocol antimicrobial susceptibility testing considerations: The Achilles’ Heel of the Trojan Horse? J. Clin. Microbiol. 59, DOI:10.1128/JCM.00951-20 (2020)
- Stanowisko Zespołu Roboczego ds. oznaczania lekowrażliwości zgodnie z zaleceniami EUCAST w sprawie najczęściej zgłaszanych pytań dotyczących stosowania rekomendacji EUCAST, wersja 5.0, 15 grudnia 2021
https://korld.nil.gov.pl/wp-content/uploads/2022/03/Stanowisko-Zespolu-Roboczego-wersja-5_0-2021.pdf (14.03.2023) - Szewczyk M.E.: Diagnostyka bakteriologiczna. Wydawnictwo Naukowe PWN SA, Warszawa, 2019
- The European Committee on Antimicrobial Susceptibility Testing – EUCAST, Guidance document on broth microdilution testing of cefiderocol, December 2020.
https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Guidance_documents/Cefiderocol_MIC_testing_EUCAST_guidance_document_201217.pdf (14.03.2023) - The European Committee on Antimicrobial Susceptibility Testing „Clinical breakpoints – breakpoints and guidance”, January 1, 2022,
https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf (14.03.2023) - Trifonova A., Strateva T.: Stenotrophomonas maltophilia – a low-grade pathogen with numerous virulence factors, Infectious Diseases, 51, 168–178 (2019)
- Trignano E., Manzo M.J., Fallico N., Maffei M., Marongiu F., Campus G.V., Rubino C.: First report of digital skin ulcer with Stenotrophomonas maltophilia infection in an immunocompetent patients. In Vivo, 28, 259–261 (2014)
- Umar Z., Ashfaq S., Parikh A., Ilyas U., Foster A., Bhangal R., Khan J., Nassar M.: Stenotrophomonas maltophilia and urinary tract infections: a systematic review. Cureus. 14, DOI: 10.7759/cureus.26184 (2022)
- Walkty A., Adam H., Baxter M., Denisuik A., Lagacé-Wiens P., Karlowsky J.A., Hoban D.J., Zhanel G.G.: In Vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011–2012. Antimicrob. Agents Chemother. 58, 2554–2563 (2014)
- Wang N., Tang C., Wang L.: Risk Factors for Acquired Stenotrophomonas maltophilia Pneumonia in Intensive Care Unit: A Systematic Review and Meta-Analysis. Front. Med. 8, DOI:10.3389/fmed.2021.808391 (2022)
- Wang Y.L., Scipione M.R., Dubrovskaya Y., Papadopoulos J.: Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother. 58, 176–182 (2014)
- Zając O., Laudy A.E., Tyski S.: Biofilm, pompy MDR i inne mechanizmy oporności Stenotrophomonas maltophilia na związki przeciwdrobnoustrojowe. Post. Mikrobiol. 53, 264–276 (2014)
- Zajac O.M., Tyski S., Laudy A.E.: Phenotypic and Molecular Characteristics of the MDR Efflux Pump Gene-Carrying Stenotrophomonas maltophilia Strains Isolated in Warsaw, Poland. Biology, 11, DOI:10.3390/biology11010105 (2022)
- Zhanel G.G., Karlowsky J.A. i wsp.: Imipenem-relebactam and meropenem-vaborbactam: Two novel carbapenem-_-lactamase inhibitor combinations. Drugs, 78, 65–98 (2018)
- Zhu L., Ye X. i wsp.: Fatal hemorrhagic pneumonia in patients with hematologic diseases and Stenotrophomonas maltophilia bacteriemia: a retrospective study. BMC Infect Dis. 21, DOI:10.1186/s12879-021-06420-0 (2021)
- Zöllner S.K., Kampmeier S., Froböse N.J., Herbrüggen H., Masjosthusmann K., van den Heuvel A., Reicherts C., Ranft A., Groll A.H.: Stenotrophomonas maltophilia Infections in Pediatric Patients – Experience at a European Center for Pediatric Hematology and Oncology. Front Oncol. 11, DOI:10.3389/fonc.2021.752037 (2021)